Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532779 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
A Phase 3 study, sponsored by Orexigen Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,742
- Enrollment target
NCT00532779: Completed Phase 3 study, sponsored by Orexigen Therapeutics.
NCT00532779 is a Phase 3 study that has completed, run by Orexigen Therapeutics. The registered enrollment target is 1,742 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00532779, a Phase 3 study, has completed, sponsored by Orexigen Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,742 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
Interventions
- DRUG Placebo
- BEHAVIORAL Ancillary therapy
- DRUG Naltrexone SR 16 mg/Bupropion SR 360 mg /day
- DRUG Naltrexone SR 32 mg/Bupropion SR 360 mg /day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,742 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
What the finished NCT00532779 record still lists
NCT00532779 is an interventional study that assigns participants to a tested intervention. Its 1,742 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00532779 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00532779 about?
NCT00532779 is a clinical study titled "A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects". The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
What is the current status of trial NCT00532779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,742 participants. The study started on 2007-10. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00532779?
The interventions under investigation include: Placebo (DRUG), Ancillary therapy (BEHAVIORAL), Naltrexone SR 16 mg/Bupropion SR 360 mg /day (DRUG), Naltrexone SR 32 mg/Bupropion SR 360 mg /day (DRUG).
Who is sponsoring clinical trial NCT00532779?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00532779's enrollment target sits among peer trials
1,742 129th of 2000 higher than 1,872 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04712656 · 1,739 participants
Effects of CPAP Therapy on Blood Pressure and Heart Rate Variability in Obstructive Sleep Apnea
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia